John Johnson, a director at Xeris Biopharma Holdings, Inc. (XERS), sold 15,000 shares of the company’s common stock on June 4, 2026, for a total value of $91,422. The shares were sold at a weighted average price of $6.0948 per share, with individual transaction prices ranging from $5.970 to $6.170. This transaction was executed under a Rule 10b5-1 trading plan adopted by Mr. Johnson on August 13, 2025. Following this sale, Mr. Johnson directly holds 683,083 shares of common stock.The transaction comes as Xeris Biopharma trades near $6.18 with a market capitalization of $1.06 billion. According to InvestingPro analysis, the stock appears undervalued at current levels, placing it among opportunities on the Most Undervalued list. The company has demonstrated strong fundamentals with revenue growth of 41% over the last twelve months and an impressive gross profit margin of 86%. InvestingPro offers access to over 10 additional exclusive tips for XERS, plus comprehensive Pro Research Reports covering this and 1,400+ other US equities.
On the same day, Mr. Johnson also acquired 24,193 shares of common stock through a restricted stock unit (RSU) grant. These shares were granted under the company’s 2018 Stock Option and Incentive Plan and represent a contingent right to receive one share of common stock per unit. The shares are set to vest in full upon the earlier of June 4, 2026, or the date of the company’s next annual meeting of stockholders, provided continued service through the vesting date. After this acquisition, Mr. Johnson’s direct ownership of common stock increased to 707,276 shares.
Additionally, Mr. Johnson was granted 32,996 stock options, representing the right to buy an equivalent number of common stock shares at an exercise price of $6.15 per share. These options, granted under the same 2018 Plan, have an expiration date of June 4, 2036. The stock options will vest in full upon the earlier of June 4, 2026, or the date of the company’s next annual meeting of stockholders, subject to continued service. Following this grant, Mr. Johnson directly holds 32,996 stock options.
In other recent news, Xeris Biopharma reported robust financial results for the first quarter of 2026. The company achieved a 38% increase in total revenue compared to the previous year, reaching $83.1 million. While this figure slightly missed revenue forecasts, Xeris Biopharma exceeded earnings expectations with an earnings per share (EPS) of $0.01. These developments indicate a strong performance for the company in the recent period. There have been no recent mergers or acquisitions involving Xeris Biopharma. Additionally, there were no significant analyst upgrades or downgrades reported for the company. Investors and analysts will likely be closely monitoring Xeris Biopharma’s future performance following these results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for XERS plus thousands of other stocks and find your next hidden gem with massive upside.